Q3 2025 · 13F-HR
Enavate Sciences GP, LLCholdings as filed
Filed 2025-11-14 · accession 0001953107-25-000014
$327.5M
Reported value
7
Positions
2025-09-30
Period end
The Brief · Enavate Sciences GP, LLC · Q3 2025
AI · grounded in 13F
Enavate Sciences GP, LLC established a new position in ZENAS BIOPHARMA INC ZBIO valued at $83.5M. The fund also initiated stakes in SIONNA THERAPEUTICS INC SION for $72.9M and IMMUNOME INC IMNM for $55.8M. Additional new positions include UPSTREAM BIO INC UPB, BRIDGEBIO ONCOLOGY THERAPEUT BBOT, and COMPASS THERAPEUTICS INC CMPX. Total assets under management stand at $327.5M across seven positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $83.5M | 25.5% | 3,761,359 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $72.9M | 22.3% | 2,478,030 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $55.8M | 17.0% | 4,768,583 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $46.3M | 14.1% | 2,459,703 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $30.4M | 9.29% | 2,626,946 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $27.3M | 8.32% | 7,788,150 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $11.4M | 3.47% | 3,785,802 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.